Rockwell Medical, Inc. · NASDAQ:RMTI

Rockwell Medical — Investor Presentation (February 2023)

18 slides from Rockwell Medical's investor presentation, Feb 2, 2023

1. Slide 1: Investor Presentation

   | ro © ROCKWELL MEDICAL Investor Presentation February 1, 2023 RMTI Nasdaq L

2. Slide 2: Forward-Looking Statements

   Forward-Looking Statements Certain statements in this presentation may constitute "forward-looking statements” within the meaning of federal securities laws, including, but not limited to, Rockwell's expectations regarding revenue, profitability, financial position, reliance on capital investments,

3. Slide 3: Rockwell Medical At A Glance

   Rockwell Medical At A Glance Healthcare company that develops, manufactures, and commercializes a portfolio of hemodialysis products for dialysis providers worldwide Business Second largest supplier of acid and bicarbonate concentrates for dialysis patients in the U.S. Overview Restructured business

4. Slide 4: Executive Management Team

   Executive Management Team Mark Strobeck, Ph.D. President and CEO Aqv JjIO =-Assertic= Tim T. Chole SVP, Sales and Marketing Baxter ( oo PC AMBRO. Watson Pharmaceuticais® Paul E. McGarry, CPA SVP, Finance and Chief Accounting Officer oe Alyvant (0% Deloitte & Touche s Marc Hoffman, M.D. SVP, Chief Me

5. Slide 5: Corporate Strategy

   Corporate Strategy O) Be the Global Leader in Hemodialysis Concentrates O) Provide Customers with the Highest Quality and Most Reliable Products and Services QO) Achieve Profitability and $100M+ Annual Revenue QO) Focus on Innovative, Long-Term Growth Opportunities © 2023 Rockwell Media, nc (Nasdaq:

6. Slide 6: Hemodialysis overview

   * Procedure whereby a dialysis machine and a special filter called an artificial kidney — or dialyzer — are used to clean a patient’s blood. ¢ Filters out wastes, salts, and excess fluid, and corrects electrolyte and acid-base imbalances for people who have kidney failure, or end-stage kidney diseas

7. Slide 7: U.S. In-Center Hemodialysis Concentrates Market

   U.S. In-Center Hemodialysis Concentrates Market Growth driven primarily by the increasing number of patients suffering from end-stage kidney disease TODAY 2026 ‘SOURCE: "Rockwell Medical: Concentrates Growth Strategy Report”, LE.K. Consulting LLC (2022) © 2023 Rockwell Medical, Inc. (Nasdaq: RMT) (R

8. Slide 8: Indispensable Player in a Large and Expanding Market

   Indispensable Player in a Large and Expanding Market * Rockwell Medical currently serves 1700+ dialysis clinics and growing. * Rockwell Medical is one of two manufacturers and suppliers that has scalability and transportation infrastructure to service the 7,500+ dialysis clinics in the U.S., along w

9. Slide 9: Growth Opportunities, Add New Revenue Streams

   Growth Opportunities, Add New Revenue Streams Significant Opportunity to Expand West, Access Full Sector Opportunity in the U.S. Expand West To-date, Rockwell has been geographically concentrated in the East, South, Midwest Currently, one large primary supplier in the West Represents approximately a

10. Slide 10: International Partnerships

    © ROCKWELL MEDICAL International Partnerships

11. Slide 11: Iron Deficiency Anemia | What problem needs to be solved?

    lron Deficiency Anemia | What problem needs to be solved? tron Deficiency Anemia (IDA): a Common Comorbidity in Many Diseases Moderate to severe iron deficiency and resulting anemia increases risk of... Iron Deficiency Kidney Disease 1 Can Result From’... iiaerk bali * Insufficient iron in diet te *

12. Slide 12: The Solution: Ferric Pyrophosphate Citrate (FPC) Platform

    The Solution: Ferric Pyrophosphate Citrate (FPC) Platform Indicated for the replacement of iron to maintain hemoglobin in adult patients with hemodialysis-dependent chronic kidney disease a4 Bypasses the liver, delivers iron directly to circulating transferrin’ TRIFERIC Internationally 5 * Expect ro

13. Slide 13: FPC Development Pipeline

    FPC Development Pipeline Hb Maintenance in Dialysis Patients ‘TRIFERIC® (Dialysate) Korea TRIFERIC® AVNU (I.V.) Korea ‘TRIFERIC® AVNU ((LV.) Turkey TRIFERIC® AVNU (LV.) China TRIFERIC® AVNU (1LV.) India ST ENGUI ALE Development work on Hold. See OTRAS Development work on Hold. Monenel fe Home Infusi

14. Slide 14: Financials and Milestones

    © ROCKWELL MEDICAL Financials and Milestones

15. Slide 15: Expects to Achieve Profitability in 2024

    Expects to Achieve Profitability in 2024, and Generate Annual Revenue of $100M in Next Few Years Focused on Revenue Growth Focused on Reducing Focused on Reducing Debt Cash Used in Operations (s) 6) (s) 20 $18.7M $18.7M 19 29 -220-8M s19.5m $15.3m 916.1M 8 a $5.8M as | 10 4 10 5 5 0 a N 2022 Guidanc

16. Slide 16: 2023 Milestones

    2023 Milestones Complete 100% Transfer of Baxter Business with Preferred Economics Expand Partnerships with Existing Hemodialysis Customers Grow Concentrates Business by Adding New Customers Begin Distributing Hemodialysis Products in the West Increase TRIFERIC® Sales in Korea (Jeil Pharmaceutical)

17. Slide 17: Why Invest in Rockwell Medical?

    Why Invest in Rockwell Medical? C) Revenue-Generating Business QO) Path Toward Growth and Profitability C) Strengthened Financial Position C) De-Risked Clinical Development and Regulatory Path Q) No Additional Fundraising Anticipated in Order to Achieve Profitability LJ Attractive Valuation © 2023 R

18. Slide 18: MEDICAL

    ©) ROCKWELL MEDICAL www.rockwellmed.com IR@rockwellmed.com

Rockwell Medical — Investor Presentation (February 2023) on 6ix